Regeneron Pharmaceuticals Inc (REGN) is now in the Fair zone, suggesting that its current forward PE ratio of 17.21 is considered Fairly compared with the five-year average of 16.41. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 693.78 to 959.82 according to relative valuation method.

Relative Value

Fair Zone

693.78-959.82

Current Price：785.27

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Regeneron Pharmaceuticals Inc (REGN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Regeneron Pharmaceuticals Inc (REGN) has a current Price-to-Book (P/B) ratio of 2.58. Compared to its 3-year average P/B ratio of 3.16, the current P/B ratio is approximately -18.41% higher. Relative to its 5-year average P/B ratio of 3.42, the current P/B ratio is about -24.58% higher. Regeneron Pharmaceuticals Inc (REGN) has a Forward Free Cash Flow (FCF) yield of approximately 5.30%. Compared to its 3-year average FCF yield of 4.71%, the current FCF yield is approximately 12.52% lower. Relative to its 5-year average FCF yield of 5.84%, the current FCF yield is about -9.27% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for REGN competitors is 5.73, providing a benchmark for relative valuation. Regeneron Pharmaceuticals Inc Corp (REGN.O) exhibits a P/S ratio of 5.37, which is -6.3% above the industry average. Given its robust revenue growth of 2.51%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of REGN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of REGN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is REGN currently overvalued or undervalued?

What is Regeneron Pharmaceuticals Inc (REGN) fair value?

REGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 693.78 to 959.82 according to relative valuation method.

How does REGN's valuation metrics compare to the industry average?

The average P/S ratio for REGN's competitors is 5.73, providing a benchmark for relative valuation. Regeneron Pharmaceuticals Inc Corp (REGN) exhibits a P/S ratio of 5.37, which is -6.30% above the industry average. Given its robust revenue growth of 2.51%, this premium appears unsustainable.

What is the current P/B ratio for Regeneron Pharmaceuticals Inc (REGN) as of Mar 02 2026?

As of Mar 02 2026, Regeneron Pharmaceuticals Inc (REGN) has a P/B ratio of 2.58. This indicates that the market values REGN at 2.58 times its book value.

What is the current FCF Yield for Regeneron Pharmaceuticals Inc (REGN) as of Mar 02 2026?

As of Mar 02 2026, Regeneron Pharmaceuticals Inc (REGN) has a FCF Yield of 5.30%. This means that for every dollar of Regeneron Pharmaceuticals Inc's market capitalization, the company generates 5.30 cents in free cash flow.

What is the current Forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN) as of Mar 02 2026?

As of Mar 02 2026, Regeneron Pharmaceuticals Inc (REGN) has a Forward P/E ratio of 17.21. This means the market is willing to pay $17.21 for every dollar of Regeneron Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Regeneron Pharmaceuticals Inc (REGN) as of Mar 02 2026?

As of Mar 02 2026, Regeneron Pharmaceuticals Inc (REGN) has a Forward P/S ratio of 5.37. This means the market is valuing REGN at $5.37 for every dollar of expected revenue over the next 12 months.

REGN Valuation